Ori Gutwerg

Ori joined INSUD Pharma in 2014 as Vice President of Business Development and Commercial Operations and was entrusted to build the new U.S. generic business. With the launch of Xiromed in March 2016, Ori became the President and General Manager overseeing the new generic business unit. Previously, he worked for 11 years at Perrigo Pharmaceuticals and had various roles in their R&D pipeline, finance, business development, M&A activity, supply chain and sales. Ori received a BA in communications and economics from the Tel Aviv College of Management and an MBA from Tel Aviv University and the Anderson School of Management at the University of California, Los Angeles.

1 Primary Contribution